key: cord-0847351-gbjf77id
authors: B, Merrick; M, Noronha; R, Batra; S, Douthwaite; G, Nebbia; LB, Snell; S, Pickering; RP, Galao; J, Whitfield; A, Jahangeer; R, Gunawardena; T, Godfrey; R, Laifa; K, Webber; PR, Cliff; E, Cunningham; Neil, S.J.D.; H, Gettings; Edgeworth, J.D.; HL, Harrison
title: Real-world deployment of lateral flow SARS-CoV-2 antigen detection in the emergency department to provide rapid, accurate and safe diagnosis of COVID-19
date: 2021-11-18
journal: Infect Prev Pract
DOI: 10.1016/j.infpip.2021.100186
sha: 5fe8b878227a589a53372570a7ac0ccc8c2e164a
doc_id: 847351
cord_uid: gbjf77id

BACKGROUND: Point-of-care (POC) SARS-CoV-2 lateral-flow antigen detection (LFD) testing in the emergency department (ED) could inform rapid infection control decisions but requirements for safe deployment have not been fully defined METHODS: Review of LFD test results, laboratory and POC-RT-PCR results and ED-performance metrics during a two-week high SARS-CoV-2 prevalence period followed by several months of falling prevalence. AIM: Determine whether LFD testing can be safely deployed in ED to provide an effective universal SARS-CoV-2 testing capability. FINDINGS: 93% (345/371) of COVID-19 patients left ED with a virological diagnosis during the 2-week universal LFD evaluation period compared to 77% with targeted POC-RT-PCR deployment alone, on background of approximately one-third having an NHS Track and Trace RT-PCR test-result at presentation. LFD sensitivity and specificity was 70.7% and 99.1% respectively providing a PPV of 97.7% and NPV of 86.4% with disease prevalence of 34.7%. ED discharge-delays (breaches) attributable to COVID-19 fell to 33/3532 (0.94%) compared with the preceding POC-RT-PCR period (107/4114 (2.6%); p=<0.0001). Importantly, LFD testing identified 1 or 2 clinically-unsuspected COVID-19 patients/day. Three clinically-confirmed LFD false positive patients were appropriately triaged based on LFD action-card flowchart, and only 5 of 95 false-negative LFD results were inappropriately admitted to non-COVID-19 areas where no onward-transmission was identified. LFD testing was restricted to asymptomatic patients when disease prevalence fell below 5% and detected 1-3 cases/week. CONCLUSION: Universal SARS-CoV-2 LFD testing can be safely and effectively deployed in ED alongside POC-RT-PCR testing during periods of high and low disease prevalence.

universal LFD evaluation period compared to 77% with targeted POC-RT-PCR deployment alone, on background of approximately one-third having an NHS Track and Trace RT-PCR testresult at presentation. LFD sensitivity and specificity was 70.7% and 99.1% respectively providing a PPV of 97.7% and NPV of 86.4% with disease prevalence of 34.7%. ED dischargedelays (breaches) attributable to COVID-19 fell to 33/3532 (0.94%) compared with the preceding POC-RT-PCR period (107/4114 (2.6%); p=<0.0001). Importantly, LFD testing identified 1 or 2 clinically-unsuspected COVID-19 patients/day. Three clinically-confirmed LFD false positive patients were appropriately triaged based on LFD action-card flowchart, and only 5 of 95 false-negative LFD results were inappropriately admitted to non-COVID-19 areas where no onward-transmission was identified. LFD testing was restricted to asymptomatic patients when disease prevalence fell below 5% and detected 1-3 cases/week.

Rapid identification and isolation of SARS-CoV-2 patients on hospital admission is a priority to support patient movement and prevent nosocomial transmission. It is not possible using clinical criteria alone, particularly given potential for asymptomatic carriage. The turnaround time (TAT) of high-throughput laboratory PCR assays is often between 12 and 24 hours, when logistics and batching are taken into account. This means they cannot inform early triage and isolation decisions while the patient is in the emergency department (ED). This is particularly problematic at times of peak attendance and with national performance targets expecting 95% patients to be admitted or discharged within 4 hours. Clinically suspected patients are ideally moved into single-rooms whilst awaiting laboratory PCR results, but capacity can quickly be exceeded in many NHS hospitals. Clinically unsuspected COVID-19 cases subsequently diagnosed to be positive could potentially be placed in open bays, which risks nosocomial transmission.

Point-of-care (POC) SARS-CoV-2 diagnostics performed in 20-60 minutes can provide a virological COVID-19 diagnosis in ED to enable rapid isolation or cohorting to reduce risk of nosocomial transmission. Numerous POC SARS-CoV-2 RT-PCR technologies are available [1] , some with performance characteristics close to laboratory platforms; however, their cost, scalability, and requirement for verification, quality assurance, training, result recording and realworld evidence of safety and efficacy provide barriers to deployment. Lateral flow SARS-CoV-2 antigen detection devices (LFDs) are an alternative POC solution that can be obtained in near limitless supply and performed within 10-30 minutes at the bedside; however, there has been significant contention about their deployment in a clinical setting. This was in part driven by their reduced sensitivity compared with PCR [2, 3] , and because operator experience seemed to influence test performance [4] .

Nevertheless, a number of studies [5, 6] , including our own [7] , comparing RT-PCR and viral culture demonstrated that LFDs were excellent at identifying individuals likely to have infectious virus, probably the most important correlate for transmission. Consequently, as we entered the UK second wave in early December 2020 our ED made plans to introduce both targeted RT-PCR testing and then universal LFD testing linked with an action card to mitigate adverse consequences of false-positive and false-negative results. As community SARS-CoV-2 J o u r n a l P r e -p r o o f 5 Abbreviations: ED = Emergency Department. LFD = lateral flow antigen detection prevalence reached and then exceeded 1000 cases per 100,000 population [8] , POC-PCR testing was introduced on 15 th December, followed by LFD testing on 31 st December in line with NHS England calling for LFD testing to be deployed into admission pathways on 24 th December 2020 [9] .

This study was conducted to determine safety and clinical utility of including LFDs as part of the POC testing strategy through a rapid rise and then subsequent fall in prevalence of COVID-19.

This real-world study demonstrates effectiveness of this approach with a focus on the protocols used to follow up and limit the clinical impact of false positives and negative LFD results.

St Thomas' Hospital is a central London hospital with an emergency department (ED) seeing ~150,000 patients/ year. During the COVID-19 pandemic, adults (≥18 years) meeting Public Health England (PHE) COVID-19 criteria [10] at triage were either placed in a majors cubicle (28 spaces) or the resuscitation room (8 spaces), depending on severity of illness, and nonsuspected cases went to a separate majors area (10 spaces). Medical review created an additional "suspected COVID-19 cohort" based on clinical and case-contact history, radiological imaging and laboratory markers who were admitted to side rooms pending laboratory PCR result. Unsuspected patients were transferred to open bays unless there was another indication for isolation. Universal admission laboratory PCR testing was provided by high-throughput batch testing using the AusDiagnostics Multiplex Tandem SARS-CoV-2 RT-PCR assays for symptomatic patients and the Hologic Aptima® SARS-CoV-2 RT-PCR for asymptomatic patients. Tests were batched for 3 runs a day. A rapid laboratory RT-PCR test was available for selected cases using random-access Cepheid and Mobidiag technologies available 24 hours a day ( Table I) . As SARS-CoV-2 prevalence increased, ward side room capacity was exceeded leading to crowding in ED. COVID-19 positive cohort wards were opened to transfer patients directly from ED, however, the TATs for virological diagnosis precluded rapid transfer of large numbers of patients from ED. Procurement was limited to 30 tests/day and prioritised for symptomatic patients requiring hospital transfer, urgent operations or who could not easily self-isolate (Table I) .

SARS-CoV-2 LFD testing was introduced on 31 st December 2020 with training facilitated by staff experience using LFD as part of occupational-health self-testing [12] . Formal evaluation commenced on 7 th January 2021 when results were documented electronically on the ED system (Symphony). Innova LFDs were used from 7-14 th January and SureScreen LFD from 15 th January onwards due to shorter testing time (10 vs. 30 minutes). LFD results were prospectively reviewed by the clinical team every 24-hour period. During the continuation phase (22 nd January to 31 st March) results were reviewed twice-weekly. Symptomatic LFD testing was discontinued once positive predictive value (PPV) fell below 90% for two consecutive weeks POC standard operating procedure POC RT-PCR testing using Liat devices was performed as per manufacturer instructions on combined throat and nasopharyngeal swabs. Sample collection and cassette loading was performed in patient cubicles, with testing performed on two machines in the majors area.

Testing was for selected symptomatic cases as described above (Table I) 

Admission date and location, including bed space (where known), age, sex, symptoms with date of onset, admitting clinical diagnosis, POC-RT-PCR, LFD, patient mobile-phone confirmed NHS Test and Trace RT-PCR result and laboratory RT-PCR results were recorded. AusDiagnostics RT-PCR performed on the same or a separate sample taken within 48-hours, were used to evaluate LFD sensitivity and specificity. PPV and NPV of LFDs were calculated using prevalence amongst ED admitted cohort. 95% confidence intervals were determined using the Wilson/Brown binomial test. All clinical SARS-CoV-2 genome sequence reports in the caseof LFD false-negative patients and for any sequenced first-isolate taken >8 days post-admission (defined as a hospital-acquired case) between January 7 th and February 28th were reviewed that used difference of <= 1 SNP difference to define linkage [13] . During the continuation phase data on admission bed space, symptom onset, and assessing clinician's impression were not collected. Breach data was retrospectively collected from 1 st December 2020 until 28 th 

As symptomatic cases increased, the number of POC-RT-PCR tests performed exceeded the 30/day procurement limit for five consecutive days from 26 th December (Figure 2b ). This prompted introduction of LFD testing with an action card on December 31 st (Figure 1 ). Between (Table IIa) . The majority without a confirmatory PCR test were not admitted (n=346, 86.9%). Comparing LFD with any RT-PCR results, the sensitivity and specificity was 70.7% and 99.1% respectively, with a positive predictive value (PPV) of 97.7% and negative predictive value (NPV) of 86.4%. These figures were calculated based on disease prevalence of 34.7% across the 2-week period (Table IIa) 

This study demonstrates the diagnostic, infection control and operational benefit of introducing universal SARS-CoV-2 LFD testing alongside laboratory and targeted POC-RT-PCR testing during periods of both high (up to 50%) and then low (<5%) prevalence. It enabled a virologicaldiagnosis of COVID-19 for 93% of patients while in ED, compared with 77% during the preceding two weeks, when a combination of community NHS Test and Trace results and targeted POC RT-PCR testing was available. This improved the efficient flow of patients into the hospital evidenced by ED-breach data and also identified 1-2 clinically-unsuspected COVID-19 patients per day when prevalence was high and 1-3 per week when low. This prevents inadvertent admission of asymptomatic COVID-19 patients to non-COVID-19 wards that can lead to hospital transmission [15] , which has significant individual patient impact alongside resource implications from contact tracing and prolonged contact isolation and closure of cohort bays.

LFD testing was introduced with an ED action card that limited adverse clinical consequences from the many expected false-negative results and few false-positive results each day during the high prevalence period. The 95 false-negative LFD results were exclusively in samples with low viral loads (CT ≥25) and most already had a recent NHS Test and Trace result or had subsequent POC RT-PCR tests in ED informed by the action card. Consequently, only 5 patients were inappropriately placed on a COVID-19 negative ward over the 2-weeks. All were moved within 10 hours following laboratory PCR results and no onward transmission was identified by either hospital contact tracing combined with reviewing genome sequence results of isolates from available probable and definite hospital-acquired cases, important given potential for cryptic linkage between wards [13] . In addition, only three genuine false-positive results were identified from 906 tests during the high prevalence period. All were asymptomatic and clinically unsuspected of having COVID-19 thus were isolated pending a confirmatory RT-PCR result. Together, this real-world evidence demonstrates safe deployment of universal LFDs in ED to inform admission placement decisions.

An alternative to introducing LFD testing could have been to increase POC RT-PCR testing capacity, perhaps placing devices in every assessment cubicle or together in a dedicated ED laboratory. Two Liat devices providing rapid SARS-CoV-2 and influenza A/B detection were in J o u r n a l P r e -p r o o f Abbreviations: ED = Emergency Department. LFD = lateral flow antigen detection place and there was extensive experience from their use during previous influenza seasons [16] ; however, universal POC-RT-PCR testing was not possible due to procurement limitations, and it would have been a much more expensive and operationally challenging solution to deploy at scale. There was nevertheless considerable debate about the appropriateness of using LFDs given unquantifiable potential for adverse patient placements due to inferior performance characteristics compared with commercially-available POC-RT-PCR tests and potential for operator errors. Confidence to proceed was supported by our evidence that LFD results showed good correlation with presence of infectious virus [7] . This highlights the benefit of having University research laboratories linked with infectious diseases diagnostic laboratories to enable a rapid response to emerging pathogens [17] . In summary, this study adds significantly to the literature providing evidence that SARS-CoV-2 LFD testing can be safely deployed in a healthcare setting to realise clinical and operational benefits [18] [19] [20] [21] [22] [23] [24] [25] . Since completion, LFD testing has been extended to other clinical areas facilitated by manual result entry into POC glucometer machines and development of a smartphone application that scans the QR-coded LFD cassette results into the EPR pathology result section. This facilitated result dissemination and removed the need for visual reading and manual entry, preventing occasional incorrect result recording due to human error. This coming winter now presents a different challenge with predicted increases in influenza, perhaps more than COVID-19, and potential for co-infection. Distinct COVID-19, COVID-19 plus influenza coinfection and influenza cohorts may be required, which will need a different POC testing strategy for efficient triage informed by a new action card. There may also be better access to a wider range of POC-RT-PCR tests detecting both COVID-19 and influenza A/B, and influenza A/B antigen LFDs are being developed [26] . It emphasises the need for continuous improvement in the approach to diagnosis of emerging and seasonal respiratory viral infections. It also illustrates the contribution that real-world POC studies can make in defining the characteristics of a responsive learning healthcare system, alongside data from formal clinical trials and laboratory evaluations of performance characteristics and turn-around time [27] . Abbreviations: ED = Emergency Department. LFD = lateral flow antigen detection 

Point-of-care testing detection methods for COVID-19

COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: A national systematic evaluation of sensitivity and specificity for mass-testing

Scientific Advisory Group for Emergencies. Innova Lateral Flow SARS-CoV-2 Antigen test accuracy in Liverpool Pilot: Preliminary Data

Preliminary report from the Joint PHE Porton Down & University of Oxford SARS-CoV-2 test development and validation cell: rapid evaluation of lateral flow viral antigen detection devices (LFDs) for mass community testing

The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro

Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture

Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a laboratory evaluation study

COVID-19) Cases: Greater London Authority

Lateral flow device testing for emergency department patient pathways

COVID-19: investigation and initial clinical management of possible cases. Date Accessed 6th

Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study

Abbreviations: ED = Emergency Department. LFD = lateral flow antigen detection

Asymptomatic staff testing for COVID-19. Date Accessed 6th

Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission

Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings

The burden of nosocomial covid-19: results from the Wales multi-centre retrospective observational study of 2518 hospitalised adults

Impact of a multiplex PCR point-of-care test for influenza A/B and respiratory syncytial virus on an acute pediatric hospital ward

Lessons learnt: the role of academia and industry in the UK's diagnostic testing response to COVID-19

SARS-CoV-2 Antigen Rapid Immunoassay for Diagnosis of COVID-19 in the Emergency Department

Diagnostic accuracy and utility of SARS-CoV-2 antigen lateral flow assays in medical admissions with possible COVID-19

Performance Evaluation of Serial SARS-CoV-2 Rapid Antigen Testing During a Nursing Home Outbreak

SARS-CoV-2 Antigen Detection to Expand Testing Capacity for COVID-19: Results from a Hospital Emergency Department Testing Site

Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR

Implementing SARS-CoV-2 Rapid Antigen Testing in the Emergency Ward of a Swiss University Hospital: The INCREASE Study

Abbreviations: ED = Emergency Department. LFD = lateral flow antigen detection

Comparing the diagnostic accuracy of point-of-care lateral flow antigen testing for SARS-CoV-2 with RT-PCR in primary care (REAP-2)

Diagnostic accuracy of two commercial SARS-CoV-2 antigendetecting rapid tests at the point of care in community-based testing centers

Coronavirus: A timeline of how the deadly COVID-19 outbreak is evolving. Date Accessed 26th

Assessing the value of diagnostic tests: a framework for designing and evaluating trials

We would like to thank all the clinical staff at St Thomas' hospital who cared for the patients involved in this study, as well as the point-of-care testing team.